Design Potent Telomerase Inhibitors Using Structure Based Approaches

Target based drug design is increasingly gaining more attention for anticancer therapy. Telomere are repetitive nucleotide sequences that are present at the end of chromosomal DNA. Shortening of telomere length has been associated with cellular senescence and the aging process. In cancerous cell telomerase is activated which maintain the length of telomere and leads to cell proliferation. Therefore, telomerase is the major recognised target for the development of better cancer therapeutics. In this study we have designed novel derivatives of telomerase inhibitors as anticancer agents. In continuation of this we have generated structure based pharmacophore model of telomerase and screened ZINC database to identify compounds with similar pharmacophoric features and further subjected to Glide molecular docking and ADMET prediction.